Trials / Terminated
TerminatedNCT02712944
Testosterone Replacement in Renal Failure
Effect of Testosterone Replacement on Erythropoietin Stimulating Agent Use in End Stage Renal Disease Patients
- Status
- Terminated
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 21 (actual)
- Sponsor
- Texas Tech University Health Sciences Center · Academic / Other
- Sex
- Male
- Age
- 18 Years – 80 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this trial is to evaluate the effect of testosterone replacement in men with renal failure (on dialysis) who also have low testosterone. Specifically, the investigators will assess the change in requirement of Erythropoietin Stimulating agents.
Detailed description
Testosterone replacement can increase hemoglobin count. This can therefore decrease the requirement of Erythropoietin Stimulating agents.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Testosterone | Testosterone |
| DRUG | Saline | Placebo |
Timeline
- Start date
- 2016-07-01
- Primary completion
- 2018-03-01
- Completion
- 2018-03-01
- First posted
- 2016-03-18
- Last updated
- 2019-05-28
Locations
1 site across 1 country: United States
Source: ClinicalTrials.gov record NCT02712944. Inclusion in this directory is not an endorsement.